Comparing eye injections for diabetic macular edema
Part of Brain & nervous system, Eyes & vision, Hormones & metabolism clinical trials.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes.
- You have diabetic macular edema (swelling in the center of your retina) with cysts and a retinal thickness over 280 microns.
- You have not had any other disease affecting the macula (the central part of your retina).
- You have not had any prior surgery on the retina or vitreous gel (the jelly inside the eye).
- You have not had previous laser treatment on the macula or widespread laser for diabetic eye disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single steroid injection around the back of the eye can improve vision in people with diabetic macular edema (swelling in the center of the retina that blurs vision). It is for people who have not yet had any other eye treatments for this condition.
This study tests whether receiving anti-VEGF injections for diabetic macular edema (DME) at home is as safe and effective as getting them in the hospital. You would use a home device to check your vision and eye scans, and a nurse would visit for injections.
This trial looks at which long-acting steroid implant works better for diabetic macular swelling that did not improve enough with past treatments. It may help patients by testing a treatment option aimed at improving vision when other eye injections have not worked well.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.